Background Cabozantinib has shown clinical activity in combination with checkpoint
inhibitors in solid tumours. The COSMIC-312 trial assessed cabozantinib plus atezolizumab …

Background The multikinase inhibitor C has shown promising clinical activity in combination
with immune checkpoint inhibitors, including A, in multiple tumor types. COSMIC-312 …

Cabozantinib is an oral tyrosine kinase inhibitor that targets VEGFR, MET and the TAM
(TYRO3, AXL, MER) family of kinase receptors. In addition to their role in tumor growth and …

Introduction: Cabozantinib has been approved by the European Medicine Agency (EMA) for
hepatocellular carcinoma (HCC) previously treated with sorafenib. Cabozantinib is also …

Background Understanding patients' experience of cancer treatment is important. We aimed
to evaluate patient-reported outcomes (PROs) with atezolizumab plus bevacizumab versus …

Objective In the phase 3 CELESTIAL trial, cabozantinib improved overall survival (OS) and
progression-free survival (PFS) compared with placebo in patients with previously treated …

Hepatocellular carcinoma (HCC) is rising in incidence and remains a leading cause of
cancer-related death. After a decade of disappointing trials following the approval of …

Background Immunotherapy with immune checkpoint inhibitors combined with an anti-
angiogenic tyrosine-kinase inhibitor (TKI) has been shown to improve overall survival versus …

207 Background: C, an inhibitor of MET, VEGFR, and AXL, has previously shown clinical
activity in pts with advanced HCC. This phase 3 trial (NCT01908426) evaluated C vs P in …

Background & Aims IMbrave150 demonstrated that atezolizumab plus bevacizumab led to
significantly improved overall survival (OS) and progression-free survival (PFS) compared …